[Is it presently reasonable to propose prostate cancer screening? Questions and answers].
Prostate cancer is the most frequently non-dermatologic tumor diagnosed in Europe. The validity of its screening has been demonstrated by 2 prospective randomized studies including over 160000 patients. However, prostate cancer screening remains controversial because it may lead to overtreatment; moreover, some patients may experience significant functional side effects after surgery and radiotherapy. Integrating this with the individual health situation leads to invite patients to early diagnosis once substantial information has been provided. If cancer is diagnosed, its management is recommended in a multidisciplinary center whose recruitment volume is significant.